Board of Directors

Meg Spencer, Chairman, Director and Chief Executive Officer - Ms. Spencer is co-founder, Chairman, and Chief Executive Officer of Hamilton Thorne, Inc. and Chairman, a Director and Chief Executive Officer of Hamilton Thorne, Ltd. She brought 17 years experience in the field of regenerative medicine and other technology markets to Hamilton Thorne when she founded the company. She founded two previous companies, taking each from start-up to global market leadership in their respective sectors. Hamilton Equine Systems, Inc., a high tech veterinary products company, was successfully sold at an attractive return on investment for its investors. Hamilton-Thorne Research offered reproductive toxicology testing systems for the study of the effects of chemicals, pesticides and prescription drugs on human and animal reproduction. Ms. Spencer has identified important problems in Stem Cell, transgenic research and molecular diagnostics; she has raised capital, sought and licensed key enabling technologies, forged accelerated university product development programs, established international distribution channels and strategic sales alliances, and pushed through development of proprietary in-house technologies to revolutionize stem cell and transgenic research.

Diarmaid H. Douglas-Hamilton, Director, Corporate Secretary and Chief Technology Officer - Mr. Douglas-Hamilton is a co-founder, Chief Technology Officer and Senior Vice-President Research & Development of Hamilton Thorne and a Director and Chief Technology Officer of Hamilton Thorne, Ltd. He was formerly Principal Scientist and Project Director at Avco Everett Laboratories, and Technical Director at Eaton Corp. He is a physicist with broad specialties in optics and lasers, holding multiple patents in assorted fields. Mr. Douglas-Hamilton has extensive experience in effectively managing large and small research and development projects. Mr. Douglas-Hamilton was formerly a director of Hamilton Thorne, Inc.

Dean Gendron, Director, Member of Compensation Committee and Audit Committee - Mr. Gendron is the founder, President and CEO of Redan Capital Incorporated, a company that provides M&A, corporate finance and investment banking advisory services to early stage and developed private and public companies. Mr. Gendron provided key leadership in the financing and growth of Critical Outcome Technologies Inc., a drug discovery and development company, including its financing activities and concurrent reverse takeover of Aviator Petroleum Corp., a TSX Venture Exchange-listed capital pool company, and served as a director of Critical Outcome Technologies Inc. until September 2008. Mr. Gendron was the President and Chief Executive Officer of DDP Therapeutics, an early stage drug development company and a founder and is a Director of KCC Capital Corporation, a TSX Venture Exchange-listed capital pool company. Mr. Gendron was formerly President and Chief Executive Officer of Calotto Capital, Inc.

Bruno Maruzzo, Director and Chair of Compensation Committee - Mr. Bruno Maruzzo is President of TechnoVenture Inc., a technology consulting company. Mr. Maruzzo has worked with a variety of public and private high technology companies in the computer, medical instrumentation and biotechnology sectors, where he held positions in a range of areas including business development, corporate development, investor relations, engineering management and general management. He has also worked in the venture capital field, sourcing, assessing and making investments in early-stage technology-based companies in Canada and the US. Mr. Maruzzo is currently a director of Pinetree Capital Ltd., a TSX-listed company, and Critical Outcome Technologies Inc., Minati Capital, Drift Lake Resources, Cleanfield Alternative Energy, all TSX Venture Exchange-listed companies.

Scott A Pearson, Director and Member of Audit Committee - Mr. Pearson is President and CEO of Protonex Technology Corporation, a leader in the research and sale of breakthrough fuel cell systems.  The company is listed on the London Stock Exchange’s Alternative Investment Market.  Previously, Mr. Pearson has served as President of the Powerware Corporation, a US$800M global manufacturer of uninterruptible power systems, as President of Cookson Performance Solutions where he grew revenues from US$3M to over US$40M and as Product Manager for several digital products  at the Eastman Kodak Corporation.  Mr. Pearson was formerly a director of Hamilton Thorne, Inc.

Robert J. Potter, Director Chair of Compensation Committee - Mr. Potter is President and CEO of Expressor Software, a new data integration and data engine software company. Mr. Potter has served with Sigma Partners, a leading venture group in Boston, and was formerly President and CEO of Kalido Corporation, where he grew revenues from US$5.6M to US$18.5M in two and one half years; Executive Vice President of Iona Technologies where he engineered growth of the company into a US$180M global enterprise, and Senior Vice President of Worldwide Sales and Services at Object Design, Inc., where he grew sales from US$1M to US$38M and the Inc 500 award as the fastest growing company in the USA. Mr. Potter was formerly a director of Hamilton Thorne, Inc.

Daniel K. Thorne, Director and Member of Compensation Committee - Mr. Thorne is President of Star Lake Capital, Inc., a private venture capital firm that invests in technology companies, and its related fund, Star Lake Bioventures LLC. Mr. Thorne is also a Trustee of the Wildlife Conservation Society, a Trustee of the National Trust for Historic Preservation, and a member of the board of Environmental News Television, Inc.    Mr. Thorne was formerly a director of Hamilton Thorne, Inc.

Return to Top